Diagnostic Hybrids in the Media
Quidel Corporation Announces Definitive Agreement to Acquire Diagnostic Hybrids January 11, 2010Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care diagnostic tests, announced today the signing of a definitive agreement to acquire privately held Diagnostic Hybrids, Inc. for approximately $130 million in cash.
 | DHI Featured in Columbus Dispatch |
Diagnostic HYBRIDS' response to the current outbreak of H1N1 Influenza A virus was covered in the Columbus Dispatch on May 6, 2009. To read the full story, please visit the Columbus Dispatch website.
read more>>Featured Products
|
Thyretain TSI Reporter BioAssay
With a procedure for easy handling, a patented testing technology, specific TSI detection and quick turnaround time, Thyretain offers a superior product coupled with accurate results that improve patient care and laboratory workflow. read more>> |
|
D3 IFA Enterovirus ID Kit
Rapid isolation and identification of Enterovirus infections is essential for proper patient management. Diagnostic HYBRIDS has used its MixedCellsTM technology to combine an engineered BGMK cell line with hDAF (human Decay Acceleration Factor, a cellular receptor for multiple Enteroviruses)... read more>> |
|
D3 FastPointTM L-DFATM Influenza A/Influenza B Virus Identification Kit
D3 FastPoint is a Revolutionary Technology that allows for the identification of Influenza A & B with DFA accuracy in under 25 minutes from specimen receipt to virus identification. read more>> |
